{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:54Z","timestamp":1793394114232,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA142714"],"award-info":[{"award-number":["R01 CA142714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canep.2021.102090","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T03:38:22Z","timestamp":1641353902000},"page":"102090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes"],"prefix":"10.1016","volume":"76","author":[{"given":"Amy M.","family":"Linabery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Roesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica D.","family":"Warlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina M.","family":"Cioc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny N.","family":"Poynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2021.102090_bib1","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2021.102090_bib2","article-title":"Myelodysplastic syndromes: a new decade","author":"Volpe","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.canep.2021.102090_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.canep.2021.102090_bib4","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation","volume":"95","author":"Pedersen-Bjergaard","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.102090_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM198311033091802","article-title":"Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)","volume":"309","author":"Boice JD","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2021.102090_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0140-6736(91)90490-G","article-title":"Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours","volume":"338","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2021.102090_bib7","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","article-title":"Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha","volume":"105","author":"McLaughlin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.102090_bib8","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2016 Sub (2001\u20132014). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2017, based on the November 2016 submission."},{"key":"10.1016\/j.canep.2021.102090_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2021.102090_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.leukres.2005.06.011","article-title":"Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology","volume":"30","author":"Disperati","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.canep.2021.102090_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.leukres.2011.12.020","article-title":"Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies","volume":"36","author":"Castillo","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.canep.2021.102090_bib12","first-page":"939","article-title":"Occupational exposures and haematological malignancies: overview on human recent data","volume":"16","author":"Descatha","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2021.102090_bib13","first-page":"489","article-title":"Lifestyle factors and the risk of adult leukemia in Canada","volume":"16","author":"Kasim","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2021.102090_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ijc.30420","article-title":"Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study","volume":"140","author":"Poynter","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canep.2021.102090_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canep.2015.12.005","article-title":"Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Poynter","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2021.102090_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.21941","article-title":"Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population","volume":"86","author":"Lv","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.canep.2021.102090_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428199409049654","article-title":"Hematopoietic malignancies and related disorders among benzene-exposed workers in China","volume":"14","author":"Travis","year":"1994","journal-title":"Leukemia & lymphoma"},{"key":"10.1016\/j.canep.2021.102090_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00277-006-0128-y","article-title":"A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro)","volume":"85","author":"Pekmezovic","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canep.2021.102090_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1365-2141.2001.02645.x","article-title":"Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France","volume":"112","author":"Nisse","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.canep.2021.102090_bib20","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/sj.leu.2403945","article-title":"Risk factors of myelodysplastic syndromes: a case-control study","volume":"19","author":"Strom","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.canep.2021.102090_bib21","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/aje\/kwp074","article-title":"Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort","volume":"169","author":"Ma","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.canep.2021.102090_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canep.2021.102090_bib23","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canep.2021.102090_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database","volume":"38","author":"Wilson","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2021.102090_bib25","first-page":"371","article-title":"Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?","volume":"19","author":"Dalamaga","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2021.102090_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canep.2021.102090_bib27","first-page":"937","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009"},{"key":"10.1016\/j.canep.2021.102090_bib28","first-page":"1083","article-title":"Medical conditions and risk of adult myeloid leukemia","volume":"23","author":"Johnson","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2021.102090_bib29","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190802165946","article-title":"Association of thyroid disease and thyroid autoimmunity with multiple myeloma risk: a case-control study","volume":"49","author":"Dalamaga","year":"2008","journal-title":"Leukemia lymphoma"},{"key":"10.1016\/j.canep.2021.102090_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.15163","article-title":"Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study","volume":"181","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.canep.2021.102090_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut."},{"key":"10.1016\/j.canep.2021.102090_bib32","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.canep.2021.102090_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00277-018-3302-0","article-title":"Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes","volume":"97","author":"Montoro","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canep.2021.102090_bib34","article-title":"Autoimmune disease in CMML-the chicken or the egg? Best practice & research","volume":"33","author":"Ambinder","year":"2020","journal-title":"Clin Haematol"},{"key":"10.1016\/j.canep.2021.102090_bib35","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2021.102090_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.canep.2021.102090_bib37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid Leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canep.2021.102090_bib38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2021.102090_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.41091","article-title":"Timing of elevations of autoantibody isotypes prior to diagnosis of rheumatoid arthritis","volume":"72","author":"Kelmenson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.canep.2021.102090_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7326\/M18-0737","article-title":"Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers","volume":"169","author":"Ebert","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.canep.2021.102090_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12032-018-1094-7","article-title":"The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes","volume":"35","author":"Castelli","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.canep.2021.102090_bib42","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/10428194.2016.1267350","article-title":"The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome","volume":"58","author":"Falantes","year":"2017","journal-title":"Leukemia lymphoma"},{"key":"10.1016\/j.canep.2021.102090_bib43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.leukres.2015.05.007","article-title":"Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes","volume":"39","author":"Balleari","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.canep.2021.102090_bib44","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/bloodadvances.2020003381","article-title":"Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study","volume":"5","author":"Rozema","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.canep.2021.102090_bib45","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2021.102090_bib46","doi-asserted-by":"crossref","unstructured":"J.S. Hecker, L. Hartmann, J. Riviere, M.C. Buck, M. van der Garde, M. Rothenberg-Thurley, et al., CHIP & HIPs: Clonal Hematopoiesis is Common in Hip Arthroplasty Patients and Associates with Autoimmune Disease. Blood, 2021.","DOI":"10.1182\/blood.2020010163"},{"key":"10.1016\/j.canep.2021.102090_bib47","unstructured":"(CDC) Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System Survey Data. In: U.S. Department of Health and Human Services Centers for Disease Control and Prevention, editor. Atlanta, Georgia, 2018."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121002071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121002071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:27:21Z","timestamp":1761802041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782121002071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":47,"alternative-id":["S1877782121002071"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2021.102090","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2021.102090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102090"}}